Table 1 Patient’s characteristics.
| Â | Case 1 | Case 2 | Case 3 |
|---|---|---|---|
Demographics | |||
Age | 49 | 39 | 66 |
Race | white | white | white |
ECOG | 1 | 0 | 0 |
Disease characteristics | |||
Receptor status at diagnosis | ER < 1%, PR 0%, Her2 0%, AR 100% | ER 0%, PR 0%, Her2 1 + , AR 0% | ER 0%, PR 0%, Her2 1 + , AR 0% |
Histology | IDC | IDC | IDC |
Disease stage | metastatic | metastatic | metastatic |
Metastatic sites | lung, mediastinal LN, upper gastrohepatic LNs, adrenal glands, bone | lungs, hilar LNs, chest wall | CNS, lung, hilar and mediasinal LN, subcutanous |
Site of metastasis | > 3 | > 3 | > 3 |
Prior therapy | |||
Neoadjuvant or adjuvant | AC x 4c | AC x 2c, TC x 2c | AC-T |
Adjuvant radiation | yes | yes | no |
Disease-free interval | 1 mo | 5 mo | 46 mo |
Metastatic systemic treatment | none | none | none |
Surgery | bilateral mastectomies | lumpectomy | bilateral mastectomies |
Olaparib/durvalumab | |||
Best response | PD | SD | PR |
Best response duration | PD | 7 mo | 15.1 |
Overall response | PD | PD | PD |
Survival (months) | 1.77 | 12.53 | Not reached |
